Smith+Neighbour, a FTSE 100 medical‑products company headquartered in the United Kingdom, said on Wednesday that its chief financial officer, John Rogers, will leave the firm at the close of September. Rogers, who assumed the CFO role in early 2024, is moving to an external position in the United States.
Interim leadership appointed
The company named senior vice‑president of finance and group controller Pierre Palassian as interim chief financial officer. Palassian, who joined Smith+Neighbour in 2017, previously held senior finance roles at AbbVie and Abbott Laboratories.
Context of the change
The leadership transition follows Smith+Neighbour’s recent decision to lower its annual revenue‑growth forecast after second‑quarter sales fell short of expectations. Weak demand for knee and hip implants in the United States and pricing pressure on skin‑substitute products contributed to the shortfall.
Financial performance under Rogers
During Rogers’s tenure, the company’s shares have risen roughly 14 % on the London Stock Exchange. Under the firm’s leaver rules, Rogers will receive no severance payment, and any outstanding incentive or share awards will lapse on September 30.
Looking ahead
Smith+Neighbour said a permanent CFO will be appointed after a thorough search. The company remains focused on stabilising its product pipeline and restoring growth momentum in its core orthopaedic and wound‑care businesses.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
